Arthur G. Mikaelian, founder and chief executive officer of Medolife pharmaceutical company, signed an agreement with the Ministry of Environment for the extraction of venom from Dominican scorpions (Rhopalurus priceps) for the creation of new generation cancer drugs. Environment Minister Francisco Dominguez Brito signed for the Dominican Republic authorizing the breeding of these scorpions for medicinal purposes in Neyba, Bahoruco province.
The company is continuing its research into the Rhopalurusabudi and Rhopalurusbonetti scorpions. The research will have a two-year duration. The Ministry of Environment granted to Medolife exclusive access to the genetic recourse that would be developed for five years.
As part of the agreement, Medolife would incorporate students in the Bahoruco area to participate in the scientific project and the company would donate 100 portions of the anti-cancer supplement Ecozine for use by the nearby communities. The company would share 5% of its net annual earnings from the marketing of Ecozine.
Several Dominican scientists are part of the Medolife team, including Js. Gilberto Concepción, Maria Inmaculada Nuñez, Ramon Enrique Feliz, and Kelvin Guerrero. Guerrero led the investigation on the biochemistry and ecology of the species of scorpion of the Family Buthidae in the Dominican Republic for Medolife in order to identify potential organic compound in the scorpion venom that can be beneficial in cancer treatment.
Escozine is promoted as a natural supplement containing polarized and potentiated, essential minerals extracted from a novel peptide, obtained from blue scorpion serum. It is processed with an exclusively owned and patented polarization technology that potentiates the active ingredients in the blue scorpion serum and supports health at a deep cellular level. The solution is colorless and odorless and can be administered orally. One bottle is used for 30 days of intake and costs US$695.
19 December 2017
